最新ニュース Cytokinetics (NASDAQ:CYTK) 株価情報

Cytokinetics

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform and raises the price target from $99 to $103.

News

Price Target

Analyst Ratings

CYTK

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Reiteration

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

<ul>
<li>Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics</li>
<li>Up to €490 Million in Commercial Milestone Payments, with</li>
<li>Tiered Royalties on Future Sales</li>
</ul>

BAYRY

Cytokinetics And Bayer Partner For Exclusive Development And Commercialization Of Aficamten In Japan

<ul>
<li>Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life</li>
<li>New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy</li>
<li>Analyses of Real-World Data Reveal Cost of Care Differences in HCM&nbsp;Across Gender, Age and Race/Ethnicity</li>
</ul>

Reported Saturday, Cytokinetics Unveils New Data On Aficamten And Hypertrophic Cardiomyopathy At AHA Scientific Sessions 2024

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
"These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia," said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. "As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating its potential to reduce the risk of adverse heart failure outcomes across the spectrum of these very high-risk patients failing guideline-directed medical therapy."

Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024

Biotech

General

Cytokinetics Initiates Phase 1 Clinical Study Of CK-4015089

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

CDTX

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

RBC Capital analyst Leonid Timashev initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform rating and announces Price Target of $80.

RBC Capital Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $80

Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.26) by 7.94 percent. This is a 0.74 percent decrease over losses of $(1.35) per share from the same period last year. The company reported quarterly sales of $463.00 thousand which missed the analyst consensus estimate of $1.20 million by 61.26 percent. This is a 22.49 percent increase over sales of $378.00 thousand the same period last year.

Earnings

Cytokinetics Q3 EPS $(1.36) Misses $(1.26) Estimate, Sales $463.00K Miss $1.20M Estimate

WIIM

Cytek Biosciences shares are trading higher following better-than-expected Q3 earnings.

Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Cytokinetics

Cytokinetics Will Provide An Update On Cardiac Myosin Modulation Programs And Global Commercial Launch Readiness For Aficamten At Its Investor And Analyst Day Today

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) price target from $75 to $85. Needham analyst Laura Martin maintained a Buy rating. Reddit shares gained 0.5% to close at $70.77 on Tuesday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from $90 to $120. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Cytokinetics shares fell 2.1% to close at $54.33 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from $13 to $9. Baird analyst Joel Beatty maintained a Neutral rating. Sage Therapeutics shares fell 4.3% to close at $6.43 on Tuesday. <a href="https://www.benzinga.com/quote/SAGE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) price target from $79 to $90. Baird analyst Colin Sebastian maintained an Outperform rating. Shopify shares gained 2.1% to close at $82.58 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $590 to $650. Deutsche Bank analyst Bryan Kraft maintained a Hold rating. Netflix shares gained 2.8% to close at $721.76 on Tuesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital raised The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) price target from $360 to $460. Loop Capital analyst Laura Champine upgraded the stock from Hold to Buy. Home Depot shares gained 1.5% to close at $414.18 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from $60 to $63. Morgan Stanley analyst Meta Marshall maintained an Overweight rating. Ciena rose 2.6% to close at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $564 to $570. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 2.4% to close at $518.35 on Tuesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Blue Owl Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from $24 to $25. JMP Securities analyst Brian McKenna maintained a Market Outperform rating. Blue Owl Capital shares fell 1.8% to close at $20.35 on Tuesday. <a href="https://www.benzinga.com/quote/OWL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) price target from $38 to $44. Baird analyst David Koning maintained a Neutral rating. Genpact shares fell 1.6% to close at $38.92 on Tuesday. <a href="https://www.benzinga.com/quote/G/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think:
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/e01feb48-33dc-4d9a-8aab-90248ce8208f" alt="" style="width:557px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

CIEN

NFLX

RDDT

SAGE

SHOP

SPGI

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and raises the price target from $90 to $120.

HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $120

Cytokinetics: On The Cusp Of Commercialization

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price ta...

Positive Clinical Outcomes Drive Buy Rating for Cytokinetics's Cardiac Myosin Modulators

Cytokinetics (CYTK) and Bayer (BAYRY) announced they have entered into a collaboration and license agreement for the exclusive development and comm...

Cytokinetics, Bayer enter collaboration and license pact for aficamten in Japan

Cytokinetics and Bayer partner to develop for aficamten in Japan

Cytokinetics (CYTK) on Tuesday announced an exclusive licensing collaboration for aficamten in Japan with Bayer (BAYRY), which JMP Securities tells...

Cytokinetics partnership demonstrates value of aficamten, says JMP Securities

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price target ...

Cytokinetics Secures Strategic Licensing Deal with Bayer, Boosting Global Prospects for Aficamten

Analyst Serge Belanger from Needham maintained a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at $72.00. Serge ...

Cytokinetics Gains 'Buy' Rating Due to Strategic Collaborations and Potential FDA Approval

Germany-based Bayer AG ($DE:BAYN) has secured a deal with U.S.-based biotech firm Cytokinetics ($CYTK) to market the latter's experimental heart dr...

Bayer Secures Deal for Cytokinetics' Heart Drug in Japan

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CYTK stock, giving a Buy rating on November 19. Salim Syed has given hi...

Cytokinetics Secures Strategic Partnership with Bayer: Analyst Recommends Buy Rating

Mizuho raised the firm's price target on Cytokinetics (CYTK) to $103 from $99 and keeps an Outperform rating on the shares. The analyst updated mod...

Comments

Cytokinetics

ニュース

最新ニュース Cytokinetics (NASDAQ:CYTK) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル